Substance Abuse, Intravenous

Phase 4 trials (2)

• elbasvir
• grazoprevir

Phase 3 trials (4)

• ledipasvir
• dalbavancin
• sofosbuvir
• oxygen (15-o) water

Phase 2 trials (1)

• buprenorphine

Other trials (3)

• ribavirin
• hepatitis-a virus (inactivated) / hepatitis-b surface antigen
• interferon alpha-2b

Organization Involved with Phase 4 Indications (2)

• Lund University
• Oregon Health and Science University

Organization Involved with Phase 3 Indications (7)

• National Institute on Drug Abuse (NIDA)
• Emory University
• Monash University
• Georgia Institute of Technology
• City University of New York
• Burnet Institute
• University of New South Wales

Organization Involved with Phase 2 Indications (1)

• Yale University

Organization Involved with Other Experimental Indications (1)

• University of California, San Francisco